Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.11B 11.38B 10.35B 19.46B 1,341B 19.78B 133B 52.13B 671B 52.64B 51.5B 2,231B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.26B 10.58B 9.62B 18.09B 1,247B 18.39B 124B 48.48B 624B 48.95B 47.89B 2,075B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.44
Extreme 28.445
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-03-31
Compliance Officer 64 2019-07-01
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
4/2/25 Issuer saleCompany 10,000 0.0094%
4/2/25 Issuer sale

Director

55,511 0.0522%
4/2/25 Issuer sale

Chief Technology Officer

265,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+133.40% 14.02B
-0.31%+2.44%+38.43%+0.77% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
-3.10%-4.84%+10.29%+160.49% 46.87B
-0.45%+1.11%-49.89%-49.57% 46.34B
-0.39%+0.91%+51.39%-20.90% 31B
-0.52%+7.01%+125.98%-35.99% 25.28B
-0.30%-0.33%+38.24%+85.63% 24.36B
+3.41%-0.31%-4.81%+196.64% 20.81B
-1.83%-2.82%+60.85%+109.32% 16.08B
Average -0.45%+1.30%+26.79%+60.87% 35.56B
Weighted average by Cap. -0.65%+1.08%+21.69%+42.17%

Financials

2023 2024
Net sales 464M 401M 377M 343M 644M 44.4B 655M 4.42B 1.73B 22.24B 1.74B 1.71B 73.89B 681M 588M 553M 503M 945M 65.1B 960M 6.47B 2.53B 32.6B 2.56B 2.5B 108B
Net income -140M -121M -113M -103M -194M -13.36B -197M -1.33B -519M -6.69B -524M -513M -22.23B -74.68M -64.5M -60.61M -55.12M -104M -7.14B -105M -710M -278M -3.58B -280M -274M -11.88B
Net Debt -481M -415M -390M -355M -667M -45.99B -679M -4.57B -1.79B -23.03B -1.81B -1.77B -76.54B -984M -850M -799M -726M -1.37B -94.1B -1.39B -9.36B -3.66B -47.12B -3.69B -3.61B -157B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock